Abstract
Background With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden. The cost of treating uncontrolled severe allergic asthma (SAA) is high encompassing a variety of direct medical costs and indirect costs. We present data on real-world healthcare utilization (direct) and school/ work absence (indirect) in uncontrolled SAA patients receiving omalizumab in the eXpeRience registry.
Highlights
With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden
Asthma-related healthcare utilization and number of days missed from school/work were recorded
Asthma-related hospitalizations Duration of hospitalization stay due to asthma, days Asthma-related emergency room visits Unscheduled asthma-related doctor visits Asthma-related medical healthcare uses* Absence from work due to asthma#, days Absence from school due to asthma#, days
Summary
With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden. Methods eXpeRience was a 2-year, global, single-arm, observational registry. Data were collected on real-world effectiveness, safety and use of omalizumab in patients with uncontrolled SAA.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
